270 related articles for article (PubMed ID: 32092140)
1. A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers.
Lu G; Conley PB; Leeds JM; Karbarz MJ; Levy GG; Mathur VS; Castillo J; Crowther M; Curnutte JT
Blood Adv; 2020 Feb; 4(4):728-739. PubMed ID: 32092140
[TBL] [Abstract][Full Text] [Related]
2. Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors.
Milling TJ; Middeldorp S; Xu L; Koch B; Demchuk A; Eikelboom JW; Verhamme P; Cohen AT; Beyer-Westendorf J; Gibson CM; Lopez-Sendon J; Crowther M; Shoamanesh A; Coppens M; Schmidt J; Albaladejo P; Connolly SJ;
Circulation; 2023 Mar; 147(13):1026-1038. PubMed ID: 36802876
[TBL] [Abstract][Full Text] [Related]
3. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
[TBL] [Abstract][Full Text] [Related]
4. Preclinical safety and efficacy of andexanet alfa in animal models.
Lu G; Hollenbach SJ; Baker DC; Tan S; Hutchaleelaha A; Curnutte JT; Conley PB
J Thromb Haemost; 2017 Sep; 15(9):1747-1756. PubMed ID: 28682477
[TBL] [Abstract][Full Text] [Related]
5. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
[TBL] [Abstract][Full Text] [Related]
6. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity: Prespecified Subgroup Analysis of the ANNEXA-4 Study in Japan.
Toyoda K; Arakawa S; Ezura M; Kobayashi R; Tanaka Y; Hasegawa S; Yamashiro S; Komatsu Y; Terasawa Y; Masuno T; Kobayashi H; Oikawa S; Yasaka M
J Atheroscler Thromb; 2024 Mar; 31(3):201-213. PubMed ID: 37635060
[TBL] [Abstract][Full Text] [Related]
7. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
8. [Andexanet alfa (ONDEXXYA
Yajima T; Higashimori M; Takata C; Sasabe T
Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
[TBL] [Abstract][Full Text] [Related]
9. Andexanet Alfa (Andexxa) Formulary Review.
Beik N; Reddy P; Sylvester KW; Connell NT; Giugliano RP; Piazza G; Connors JM
Crit Pathw Cardiol; 2019 Jun; 18(2):66-71. PubMed ID: 31094731
[TBL] [Abstract][Full Text] [Related]
10. Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban.
Benz AP; Xu L; Eikelboom JW; Middeldorp S; Milling TJ; Crowther M; Yue P; Conley P; Lu G; Connolly SJ;
Thromb Haemost; 2022 Jun; 122(6):998-1005. PubMed ID: 34996121
[TBL] [Abstract][Full Text] [Related]
11. Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy.
Demchuk AM; Yue P; Zotova E; Nakamya J; Xu L; Milling TJ; Ohara T; Goldstein JN; Middeldorp S; Verhamme P; Lopez-Sendon JL; Conley PB; Curnutte JT; Eikelboom JW; Crowther M; Connolly SJ;
Stroke; 2021 Jun; 52(6):2096-2105. PubMed ID: 33966491
[TBL] [Abstract][Full Text] [Related]
12. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation.
Carpenter E; Singh D; Dietrich E; Gums J
Ther Adv Drug Saf; 2019; 10():2042098619888133. PubMed ID: 31807265
[TBL] [Abstract][Full Text] [Related]
13. Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban.
Abuan I; Wong KH; Bolinske B; Hale KS
J Pharm Technol; 2019 Jun; 35(3):119-125. PubMed ID: 34860981
[No Abstract] [Full Text] [Related]
14. The use of andexanet alpha in the Polish setting: An interdisciplinary protocol. Expert consensus statement of the Polish Cardiac Society.
Kazimierczyk E; Dąbrowska M; Gierlotka M; Kapica-Topczewska K; Karaszewski B; Kobayashi A; Krasiński Z; Kubica J; Kułakowska A; Kurek K; Ładny R; Pleban E; Rejdak K; Rydzewska G; Słowik A; Szopiński P; Woźniak A; Tycińska A
Kardiol Pol; 2024; 82(1):123-139. PubMed ID: 38230495
[TBL] [Abstract][Full Text] [Related]
15. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
16. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
Sartori M; Cosmi B
J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
[TBL] [Abstract][Full Text] [Related]
17. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa.
Siegal D; Lu G; Leeds JM; Karbarz M; Castillo J; Mathur V; Hutchaleelaha A; Sinha U; Kitt M; McClure M; Hollenbach SJ; Curnutte JT; Conley PB; Crowther M
Blood Adv; 2017 Sep; 1(21):1827-1838. PubMed ID: 29296829
[TBL] [Abstract][Full Text] [Related]
18. Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series.
Morton C; Lista A; Jakowenko N; Salazar E; Donahue KR
J Thromb Thrombolysis; 2022 Jan; 53(1):235-239. PubMed ID: 34236614
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of andexanet alfa and prothrombin complex concentrate in reversing anticoagulation by rivaroxaban ex vivo.
Rayatdoost F; Deventer K; Rossaint R; Schöchl H; Grottke O
Br J Anaesth; 2024 Feb; 132(2):251-259. PubMed ID: 38030550
[TBL] [Abstract][Full Text] [Related]
20. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays.
Lanham HT; Viriyakitja W; Vestal M; Welsby I; Kram B
J Thromb Thrombolysis; 2024 Feb; 57(2):285-292. PubMed ID: 37932587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
